NHS England has announced that nearly 750,000 patients will benefit from new technology coming through the Innovation and Technology Payment Programme.
The programme aims to fast-track the use of new technology across the country.
These objectives align with the wider objectives of the NHS Long Term Plan, and NHS England has indicated that it will be introducing a new funding mandate for ‘proven’ health tech products as part of the implementation of the Plan.
In making the announcement, Simon Stevens said:
“From improving care for pregnant women to using digital modelling to assess heart conditions and new tests to prevent unnecessary hospitalisations for suspected heart attacks, the NHS is taking action to ensure patients have access to the very best modern technologies.”
NHS England has confirmed that 10 other tests and treatment will become part of the programme.
These innovations now supported by the programme include:
- Placental growth factor (PIGF) based test – A blood test to help rule out pre eclampsia in women suspected to have the condition who are between 20 weeks and 34 weeks plus 6 days of gestation, alongside standard clinical assessment
- High sensitivity troponin test – A blood test that when combined with clinical judgement can help rapidly rule-out heart attacks
- Gammacore – A hand-held device that delivers mild electrical stimulation to the vagus nerve to block the pain signals that cause cluster headaches
- SpaceOAR – A hydrogel injected between the prostate and rectum prior to radiotherapy, that temporarily creates a space between them so that the radiation dose to the rectum can be minimised, reducing complications like rectal pain, bleeding and diarrhoea
- HeartFlow – Advanced image analysis software that creates a 3D model of the coronary arteries and analyses the impact that blockages have on blood flow to rapidly diagnose patients with suspected coronary artery disease
Read the full NHS England announcement here.